HOUSTON and LOUISVILLE, Ky., Feb. 16, 2018 /PRNewswire/ -- NX Prenatal Inc., a privately held women's healthcare molecular diagnostic company, announced today that new clinical study data will be presented at the Society of Reproductive Investigation's (SRI) 65th Annual Scientific Meeting in San Diego, California, on March 9th, 2018. The oral presentation will describe results from a study of plasma samples obtained from pregnant mothers demonstrating proteomic biomarkers that are already unique in their expression profiles at 10-12 weeks gestation among women who go on to experience preeclampsia (PE).
The new study builds upon a series of previously published studies in which NX Prenatal has demonstrated that the enrichment of exosome and microvesicle particles from maternal blood and subsequent proteomic analysis enables risk stratification of spontaneous preterm birth (SPTB) in the first trimester of pregnancy.
"This initial data in our preeclampsia program is encouraging and demonstrates the tremendous opportunity for our NeXosome®-powered diagnostic product pipeline," commented Brian D. Brohman, CEO of NX Prenatal. "With this new data, NX Prenatal has now established the potential of its technology to enable the identification of patients early in pregnancy at increased risk for both SPTB and PE. We envision a menu of new tests from a routine blood draw that may allow more personalized care in support of healthy pregnancy outcomes."
PE can strike quickly, sometimes without any symptoms, potentially causing severe and immediate complications for the mother and fetus. In the U.S., it is reported to affect 200,000 pregnant women and is estimated to cause approximately $10 billion in healthcare costs.
About NX Prenatal NX Prenatal Inc. (NXPN) is a private US based molecular diagnostics company. The company's NeXosome® technology harvests biologically active and stable microparticles, such as exosomes, from the maternal bloodstream, to provide a real-time and non-invasive view of changing maternal and fetal tissues. This technology is enabling the development of a series of early warning blood tests for pregnancies that may result in a variety of adverse outcomes, such as spontaneous preterm birth and preeclampsia.